3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
30
Recruiting
17
Unknown
6
Terminated
5
Active not recruiting
4
Withdrawn
2
Suspended
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Paclitaxel
5
Gemcitabine
3
Nivolumab
2
Injections
2
E 7107
2
Docetaxel
2
Carboplatin
2
Antibodies, Monoclonal
2
130-nm albumin-bound paclitaxel
2
venetoclax
1
trastuzumab biosimilar HLX02
1
taxane
1
spartalizumab
1
resiniferatoxin
1
poly(I).poly(c12,U)
1
pegamotecan
1
palbociclib
1
lenvatinib
1
imisopasem manganese
1
icotinib
1
gusacitinib
1
famitinib
1
eniluracil
1
dabrafenib
1
cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV))
1
cobimetinib
1
brincidofovir
1
ammonium trichloro(dioxoethylene-O,O'-)tellurate
1
aldesleukin
1
abivertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
INDUSTRY
×
Folfox protocol
×
Clear all
NCT05033522
2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3
Suspended
150 enrolled